Redeye sees a relatively uneventful report with some positive highlights with continued progress in the EU regulatory process and the Phase 3 study in the US going ahead at full speed as it is the high season for the product. Moberg Pharma is progressing as planned, and the EU approval should be an important catalyst as we advance.